December 13, 2021 -- Smart Immune is collaborating with Memorial Sloan Kettering Cancer Center (MSK) with the goal of expanding its ProTcell pipeline to address the exhaustion of T-cell therapy and fulfill unmet medical needs in the treatment of liquid and solid cancers.
Smart Immune's T-cell progenitors (ProTcell) improves on conventional approaches to CAR T-cell therapies, which rely on mature T cells to generate a naïve, long-lasting, exhaustion-free CAR T cell population. MSK will contribute to the development of the CAR-ProTcell platform in a mouse-to-mouse model, and Smart Immune will lead the human model.
ProTcell progenitors can be efficiently transduced with a lentiviral vector, according to the groups. The collaboration will further optimize transduction and culturing conditions to perform in vitro and in vivo preclinical studies on ProTcell transduced with a CD19 CAR lentiviral vector.
No financial agreements were disclosed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
